Endolysins in dermo-cosmetic infections
Vetophage is developing an innovative therapeutic product to treat canine pyoderma, leveraging the lytic properties of endolysins.
Innovation
The treatment is currently under development.
Designed to eliminate bacterial skin infections, this treatment has demonstrated its effectiveness in both in vitro and in vivo studies. Currently, VETOPHAGE is focusing on the thorough characterization of the product and its veterinary pharmaceutical development.
These unique proteins enable:
- Reducing the bacterial load of skin lesions
- Promoting rapid and effective healing
- Reducing the size of the lesions, thereby improving the animal's comfort
future
We are seeking a partner to co-develop the product or transfer its commercialization.
We are open to any collaboration aimed at developing alternatives to antibiotics for the treatment of infectious diseases in veterinary medicine.